Diamyd® on track for Phase III with 50% LOA, targeting a multibillion-dollar market as a precision medicine game changer
As of September 15th, 2020, the company that was founded in 1984 delivered convincing top-line data – in line with medical consensus view of implementing precision medicine – consistently supporting positive effect of the first-in-class disease-modifying diabetes vaccine Diamyd® in a genetically defined group.
We initiate coverage with an Outperform rating. With a 50% LOA for the lead candidate Diamyd® and 18% LOA for Remygen® our risk-adjusted DCF valuation results in a value for Diamyd Medical of SEK 100 per share, corresponding to an equity value of approximately SEK 6.6 bn non diluted.Read More
CREATE Health delivers another exciting tech, ProMIS, which potentially could open up a world of new IP for Immunovia
In our latest research update on Immunovia, we presented our forecast of a future diagnostic regimen including a combination of proteomics and genomics-based techs to generate timely and correct diagnosis of cancer.
Published in the impactful Nature Communication Biology, Immunovia’s research arm and collaborator CREATE Health demonstrates the powerful combination of the two techs in its novel academic research project, the ProMIS platform.Read More
No one-trick pony – advancing a novel platform-based CNS company
AlzeCure has with its seven-project portfolio multiple shots at goal where each, while early stage, represents a potential multibillion-dollar opportunity.
We update our rating to Outperform and raise the target price to SEK 16 per share, corresponding to an equity value of approximately SEK 600m non-diluted, derived from risk-adjusted DCF valuation of ACD856 and ACD440.Read More
When genomics and proteomics converge, Immunovia will probably be snatched up
By being at the forefront of proteomics-based technology, nearing launch of the first to market, outstandingly accurate blood-based test for early detection of pancreatic cancer, we see Immunovia as an apparent strategic target for acquisition.
We maintain the Outperform rating and raise the target price to 300 SEK per share, corresponding to an equity value of SEK 6.8 bn non-diluted, derived from a DCF valuation of the opportunity in pancreatic cancer.Read More
Vator Securities advises Fundler on 17 MSEK Private Placement
Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 17 million.
Fundler is the first hybrid robo-advisor in the Nordics. The company’s unique savings offering combines automated investment advice and personal financial advisersRead More
Vator Securities rådger Xintela i 40,5 MSEK företrädesemission
Vator Securities agerar som finansiell rådgivare i samband med transaktionen om SEK 40,5 miljoner.
Xintela är en innovatör i utvecklingen avregenerativa cellterapier och riktade cancerterapier baserade på denpatenterade markörteknologiplattformen XINMARK®.Read More
Vator Securities advises LIDDS on 59,3 MSEK Directed and Rights Issue
Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 59,3 million.
LIDDS is a Swedish-based pharmaceutical company which develops new innovative pharmaceutical products with its proprietary drug delivery technology NanoZolid®.Read More
Vator Securities acted as Joint Bookrunner on 400 MSEK Immunovia directed share issue
Vator Securities acted as Joint Bookrunner in connection with the transaction raising SEK 400 million.
Vator Securities was involved in more than two-third of the final allocations to local and international specialist investors, thereby strongly delivering upon the company’s goal to diversify its shareholder base.Read More